dexamethasone

P=N/A, N=160, Recruiting, The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University | Not yet recruiting --> Recruiting | N=20 --> 160

P=N/A, N=780, Beijing Tsinghua Changgung Hospital; Beijing Tsinghua Changgung Hospital

P3, N=326, Recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University | Not yet recruiting --> Recruiting | Phase classification: P1 --> P3

P=N/A, N=43, Recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University | Not yet recruiting --> Recruiting

Our preliminary findings suggest patients with high baseline cytokine levels may be less likely to report placebo response for multiple symptoms. Upon further confirmation, these findings may have implications for future clinical trial design. In this exploratory analysis, we observed that patients with cancer were less likely to report placebo response for multiple symptoms if they had higher levels of baseline cytokines. These preliminary findings have important potential implications for placebo-controlled clinical trials, including patient selection, design of interventional controls, and trial interpretation. Additionally, they invite further research on possible mechanistic links between inflammation and placebo effect.

Our results suggest that the activities of some major DMEs (CYP3A4, UGT1A1, and UGT2B7) in HuH-7 cells are promoted by DEX treatment possibly through GR activation. However, unlike HPHs, HuH-7 cells fail to show transcriptional regulation of DMEs by PXR or CAR, which limits their suitability for evaluating DME induction potential of investigational drugs.

The patient exhibited poor response to bortezomib, lenalidomide, and dexamethasone therapy, necessitating a switch to carfilzomib-based treatment. This case underscores the diagnostic challenges of CD138-negative myeloma and highlights the importance of integrating morphology, immunophenotyping, and molecular profiling to inform accurate diagnosis and guide therapeutic strategies.

P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed

P3, N=70000, Recruiting, University of Oxford | Trial completion date: Jun 2036 --> Sep 2038 | Trial primary completion date: Jun 2026 --> Sep 2028

In a cisplatin-induced rat emesis model, IJ-ODW reduced kaolin intake by 18.3% (p 10 h)...STATEMENT OF SIGNIFICANCE: This study reports the rational design of an anisotropic, excipient-free buccal wafer, which overcomes the fundamental "speed-stability paradox" in mucosal delivery through its engineered bilayered architecture. By integrating ultrafast adhesion with sustained, polarity-selective release and active neuro-immune modulation, this material platform provides a scalable and dysphagia-tailored therapeutic strategy, advancing the design of multifunctional biomaterials for complex clinical needs.

P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Mar 2026 --> Jun 2026

We compared against a two-step AAV method, and treated dexamethasone (Dex) during manufacture...Dex augmented the cytotoxic activity of CAR-NK cells by promoting oxidative phosphorylation and ATP production. We designed robust, TGFβ1-resistant allogeneic CAR-NK cells using a virus-free, one-step engineering strategy, establishing a versatile, clinically scalable method for engineering metabolically fortified CAR-NK cells capable of overcoming TME-mediated suppression in solid tumors.